

October 2, 2014

# **Relmada Therapeutics Appoints Julie J. Chen As Director of Finance and Operations**

## **New Team Addition to Strengthen Financial and Business Operations**

NEW YORK, Oct. 2, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Julie J. Chen as its Director of Finance and Operations.

Ms. Chen brings almost 20 years' business experience and financial analysis to Relmada. Most recently, she has been a consultant with Credo Partners where her responsibilities have included analyzing financial models, conducting due diligence and participating in the business strategy discussions. She has also conducted data analysis, reviews of companies' operations and internal controls and collected proprietary market and industry intelligence to assist with action oriented recommendations.

Sergio Traversa, CEO of Relmada said, "We are very pleased to have Julie joining the Relmada team in the capacity of Director of Finance and Operations. She brings project management, financial and procedural know-how to the job. With her technical background in addition to her financial analytical training, she is well-positioned for success with us."

Ms. Chen was also a Senior Research Analyst at Hudson Securities, CRT Capital Group LLC and Brean Murray Carret & Co. LLC and an Associate Analyst at C.E. Unterberg Towbin. Prior to her career on Wall Street, Ms. Chen spent over 10 years in the public and private sectors as a Program Manager, Proposal Manager and Engineering Lead. Ms. Chen received her BA in Mathematics from California State University, an MS in Mathematics from Claremont Graduate School, and an MBA from Fordham University.

Ms. Chen said, "I am very excited to be joining Relmada at this important stage in the Company's development. I am excited about the science behind the Company's products, and my job will be to ensure that we utilize company resources to best deliver those products to the market and to the patients in need."

### **About Relmada Therapeutics, Inc.**

Relmada Therapeutics is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisors.

The Company's approach is expected to reduce overall clinical development risks and costs

while potentially delivering valuable products in areas of high unmet medical needs.

### **Forward-Looking Statements**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Visit our website at, [www.relmada.com](http://www.relmada.com)

SOURCE Relmada Therapeutics, Inc.